Pancreatic cancer is a devastating disease with a very poor prognosis at the time of diagnosis, usually in an advanced stage due to lack of symptoms. The 5-year survival rate is less than 9%, and pancreatic cancer is actually the fourth-leading cause of cancer death in Europe, behind lung, colorectal and breast cancer. Most pancreatic cancer patients are diagnosed at an advanced stage, which limits the choice of therapeutic interventions. Consequently, only 10 to 15% of the patients have localised disease amenable to surgery, 30-35% of the patients are considered borderline resectable, and half of the patients are presenting with metastatic disease, which is incurable. In this context, targeted alpha therapy (TAT) is an appealing therapeutic option for advanced pancreatic cancer patients, as it could overcome the resistance of cancer cells to chemotherapy and β- radiation, as well as improve overall outcome. The inherent challenge is to find an apropriate targeting vector, which can ultimately be labeled with an α-emitter. The aim of this project is therefore to transform cancer care by pioneering the development and evaluation of novel radiotheranostic pairs in highly aggressive pancreatic cancer.
The candidate will have to leverage DNA-encoded chemical libraries (DELs) along with advanced next-generation sequencing (NGS) techniques to pinpoint small molecules capable of individually producing the desired pharmaceutical effect. Upon selecting lead candidates, compounds will be labeled with 18F, 123I and 211At, before initiating preclinical investigations.
A healthy population and excellence in healthcare through research and education. This is what Erasmus MC stands for. Conducting groundbreaking work, pushing boundaries and leading the way in research, education, and healthcare. We are practical people with a high level of expertise, working hard to improve and renew the healthcare of today and the public health of tomorrow.
The candidate will be positioned at the department of Radiology and Nuclear Medicine. Our department is known for its forefront research and its state-of-the-art facilities. The concept of peptide receptor radionuclide therapy (PRRT) was introduced in our department and several theranostic agents were developed and tested from bench-to-bedside. The candidate will be a member of the RadioPharmaceutical Chemistry group and will work in collaboration with other research groups specialized in molecular imaging and targeted radiotherapy.
Applications are invited from enthusiastic and talented young researchers with an active interest in tracer development and translational radiopharmaceutical research. Qualifications and skills:
These criteria are considered advantages, but not requirements:
Before you apply please check our conditions for employment.
For more information about this position, please contact Dr. Yann Seimbille, 010 703 89 61.
If you are excited by the thought of this position and would like to apply, please do so by using the application form on our website.
No agencies please.
Did we get you excited about this position? Submit your application through the application button. You will receive a confirmation of receipt from our recruiter right away.
Based on your application, we check to see if there is a fit between us. We will let you know as soon as possible whether you are invited for an interview.
You have been invited for an interview, great! In this first meeting we get to know each other and see if You can form an idea of the position, the department and Erasmus MC. If the interview goes well usually a second interview follows.
It’s a match! Your future manager will discuss your salary and employment with you. You will also receive more information about our other terms of employment.
Your first working day has come! We are more than happy to have you. Your new department will give you a warm welcome and provide you with all the information you need. Enjoy your job at Erasmus MC!
Erasmus MC is an international leading academic hospital in Rotterdam. We are recognized as a world-class scientific research organization aiming to improve our understanding of diseases and disorders and helps to predict, treat and prevent them. We have access to the latest equipment and techniques. A working environment that gets the best out of people.
Find out more about Erasmus MC